Last reviewed · How we verify
NCT00992654
A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India
trial testing Open Label Treatment Access: Maraviroc in Human Immunodeficiency Virus (HIV). No longer available.
Quick facts
| Lead sponsor | ViiV Healthcare |
|---|---|
| Status | NO LONGER AVAILABLE |
| Study type | EXPANDED_ACCESS |
Drugs / interventions tested
- Open Label Treatment Access: Maraviroc — full drug profile →
Conditions studied
- Human Immunodeficiency Virus (HIV) — all drugs for Human Immunodeficiency Virus (HIV) →
Sponsor
ViiV Healthcare — full company profile →
Who can join
18 and older, any sex, with Human Immunodeficiency Virus (HIV). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The new protocol will allow the patients enrolled on A4001050 to have continuous access of Maraviroc and the treatment will not be interrupted until the drug is commercially available in India.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT00992654
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Human Immunodeficiency Virus (HIV)
Currently open trials in the same condition.
- NCT07071623 — A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010) · Phase 3 · recruiting
- NCT07418385 — Voluntary HIV Screening in the General Population in France · recruiting
- NCT07044297 — A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) · Phase 3 · recruiting
- NCT06814275 — Project neuroARTEMIS · NA · recruiting
- NCT06880705 — The Trans-Led Care Study · NA · recruiting
Other ViiV Healthcare trials
Trials by the same sponsor.
- NCT07393659 — A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative · Phase 3 · not yet recruiting
- NCT07525544 — A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants · Phase 1 · not yet recruiting
- NCT07275606 — A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1 · Phase 1, PHASE2 · not yet recruiting
- NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
- NCT07053384 — A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Vir · Phase 1 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00992654 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ViiV Healthcare
- Last refreshed: 27 September 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00992654.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing